This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Quetiapine in Patients With Tourette’s Disorder: An Open-Label, Flexible-Dose Study

Jonas L. de Jonge, MA; Danielle C. Cath, MD, PhD; and Anton J. L. M. van Balkom, MD, PhD

Published: July 16, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Tourette’s disorder (TD), or Gilles de la Tourette’s syndrome, is a neuropsychiatric disorder, usually starting in early childhood, characterized by multiple motor and vocal tics.

Although the etiology of TD remains largely unknown, it has been hypothesized that overactivity or hypersensitivity of the D2 receptors in the striatum plays a role.1 This hypothesis is consistent with the proved effectiveness of central D2-blocking agents like haloperidol and pimozide that decrease the intensity and frequency of tics in approximately 70% of the patients.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 68

Quick Links: Movement Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...